Core Insights - RIBER reaffirms its strategic roadmap during the Annual General Meeting, emphasizing a culture of excellence, continuous innovation, and strong customer focus to position itself at the forefront of the semiconductor industry's transformations, particularly in silicon-based integrated photonics [1][4]. Group 1: Strategic Developments - RIBER introduced ROSIE (Riber Oxide Silicon Epitaxy), an advanced platform for oxide growth on 300 mm wafers, which is fully compatible with SEMI standards, marking a significant technological breakthrough [2]. - The industrialization phase of ROSIE has commenced following a strategic partnership with the Novo Nordisk Foundation Quantum Computing Programme, which includes the qualification of the ROSIE process and the sale of the first unit scheduled for the second half of 2025 [2][3]. Group 2: Financial and Operational Highlights - The Annual General Meeting approved the statutory and consolidated financial statements for the 2024 financial year, along with a cash payout of €0.08 per share, with the ex-dividend date set for June 23, 2025 [6]. - RIBER's strategic positioning is strengthened by solid commercial momentum for its MBE equipment and the industrial rollout of ROSIE, enhancing growth and diversification potential in the semiconductor sector [4]. Group 3: Market Focus - RIBER targets several fast-growing markets, including ultra-fast optical communications, optical computing, and photonic quantum technologies, reflecting its commitment to innovation in the semiconductor industry [7]. - The company plays a crucial role in the development of advanced semiconductors used in various applications, from information technologies to 5G telecommunications networks and quantum computing [8].

RIBER completes phase I of ROSIE with a partnership agreement signed with NQCP, a leading research center in Denmark Bezons (France), June 17, 2025 – 6:00pm (CET) – RIBER, the global leader in Molecular Beam Epitaxy (MBE) equipment for the semiconductor industry, announces the signing of a three-year collaborative partnership with the Novo Nordisk Foundation Quantum Computing Programme (NQCP), a world-class research center based in Denmark. A strategic partnership to qualify the ROSIE process, the first ...

Châtillon, France, June 11, 2025 DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting Shareholders approved all proposed resolutions DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company (the “Company”), held its Combined General Meeting (the “General Meeting”). The General Meeting was chaired by Michel de Rosen, Chairman of the Company. The Company’s shareholders approved all resolutions submitted by the ...

Scholar Rock Holding (SRRK) 2025 Conference June 04, 2025 03:45 PM ET Speaker0 Fantastic. All right. Well, thank you. Good afternoon everyone. Welcome to the next session here at the Jefferies Healthcare Conference. I'm Michael Yee, a senior biotechnology analyst, and really happy to have a couple members of the ScholarRock management team with us. And importantly, this somewhat of a new team that got introduced over the last month. So I'd love perhaps, although David, you were chairman, an opportunity for ...

Company Overview - Almadex Minerals Ltd. has acquired the area covering most of the historic Petaca District in northern New Mexico through staking, as part of its regional exploration program focused on copper-gold potential [1] - The company holds a large mineral portfolio consisting of projects and NSR royalties in Canada, the U.S., and Mexico, and has significant experience in porphyry lithocap exploration [6] Exploration Focus - The Petaca District has a history of mica production and contains rare earth element (REE) bearing minerals, which were occasionally recovered as by-products of mica mining [2] - Almadex's exploration program prioritizes porphyry lithocaps and epithermal precious metal systems, although REE projects are not the company's core focus [4][5] Technical Insights - The pegmatites in the Petaca District exhibit various forms and have been noted for their elevated REE concentrations, primarily reflecting the mineral samarskite [2] - A microprobe study confirmed the presence of several minerals, including Samarskite-(Y) and polycrase-(Y), indicating a high level of niobium (Nb) and yttrium (Y) in accessory minerals [3] Future Plans - The company intends to seek a joint venture partner with expertise in REE mineral systems to explore the Petaca District [4][5] - Almadex plans to advance and test its lithocap targets in 2025, leveraging its in-house exploration capacity and drilling units [6]

TORONTO, May 12, 2025 (GLOBE NEWSWIRE) -- BULGOLD Inc. (TSXV: ZLTO) (the “Company” or “BULGOLD”) is pleased to announce the results of recent prospecting activity on the Lutila Gold Project (the “Property”), Slovakia. This information has now been validated and incorporated into the Company’s database. The Lutila exploration licence covers an area of 32.2km2 and is prospective for quartz-adularia epithermal gold mineralisation. 1. Highlights Recent prospecting activity on the Horna Klapa section of Rhyoli ...

Applied Materials (AMAT) and Lam Research (LRCX) stand out as pivotal players in the semiconductor supply chain, both offering a comprehensive range of equipment and services. Both AMAT and LRCX develop Chemical Vapor Deposition, Atomic Layer Deposition (ALD), Physical Vapor Deposition, Chemical Mechanical Planarization Epitaxy and etching tools and services for various stages of semiconductor fabrication.With the artificial intelligence (AI) boom to continue driving growth for the semiconductor industry, t ...

— Company Grants Mylan a License to Market Generic CINVANTI® and APONVIE® Beginning in June 2032 —CARY, N.C., May 6, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company entered into a settlement agreement with Mylan Pharmaceuticals, Inc. ("Mylan"), a Viatris Inc. company, to resolve the ongoing patent litigations between the parties in the U.S. District Court for the District of Delaware related t ...